Drugs / Tissue Plasminogen Activator (tPA)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02572336 Comparator | Oct 2015 → Mar 2016 | ischemic stroke | D-Pharm Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tissue Plasminogen Activator (tPA) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02572336 ↗ |
| Known as | tPA | “Tissue plasminogen activator is also called "tPA".” NCT02572336 ↗ |
| Route | Intravenous | “tPA when it is injected into a vein shortly after the stroke starts” NCT02572336 ↗ |